119O Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after ≥4 years of follow-up: BrighTNess, a randomized phase III trial

Loibl, Sibylle; Sikov, William M.; Huober, Jens; Rugo, Hope S.; Wolmark, Norman; O’Shaughnessy, Joyce; Maag, David; Untch, Michael; Golshan, Mehra; Lorenzo, J. Ponce; Metzger, Otto; Dunbar, Martin; Symmans, W. Fraser; Geyer, Charles E.

doi:10.1016/j.annonc.2021.08.400

Cited by 31 publications

(32 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Loibl et al presented their updates from the BrighTNess trial, a randomized phase III clinical trial, with three treatment arms and a total of 634 patients with TNBC: the established neoadjuvant regimen consisting of Paclitaxel alone (P) ( n = 158), Paclitaxel and Carboplatin alone (PCb) ( n = 160), and Paclitaxel, Carboplatin and the PPAR inhibitor Veliparib (PCbV) ( n = 316). Event-free survival, OS, and safety outcomes were assessed with a ≥4 years of follow-up period [ 28 ]. pCR was significantly improved when Carboplatin was added, with or without the addition of Veliparib, to Paclitaxel-based neoadjuvant chemotherapy.…”

Section: Chemotherapy For Triple Negative Breast Cancermentioning

confidence: 99%

“…pCR was significantly improved when Carboplatin was added, with or without the addition of Veliparib, to Paclitaxel-based neoadjuvant chemotherapy. Also, adding Carboplatin to Paclitaxel improved pCR and EFS without increasing myelodysplastic syndrome or acute myeloid leukemia [ 28 ]. When compared to P alone, HR for EFS with PCbV was 0.63 (95% CI: 0.43–0.92, p = 0.016), and HR for EFS with PCb was 0.57 (95% CI 0.36–0.91, p = 0.018) [ 28 ].…”

Section: Chemotherapy For Triple Negative Breast Cancermentioning

confidence: 99%

“…Also, adding Carboplatin to Paclitaxel improved pCR and EFS without increasing myelodysplastic syndrome or acute myeloid leukemia [ 28 ]. When compared to P alone, HR for EFS with PCbV was 0.63 (95% CI: 0.43–0.92, p = 0.016), and HR for EFS with PCb was 0.57 (95% CI 0.36–0.91, p = 0.018) [ 28 ]. Based on the latest American Society of Oncology (ASCO) recommendations, carboplatin may be offered to patients with TNBC to increase pathologic complete response [ 29 ].…”

Section: Chemotherapy For Triple Negative Breast Cancermentioning

confidence: 99%

See 2 more Smart Citations

Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021

Zerdan

Ghorayeb

Saliba

et al. 2022

Cancers

100

View full text Add to dashboard Cite

Breast cancer (BC) is the most common malignancy affecting women. It is a highly heterogeneous disease broadly defined by the differential expression of cell surface receptors. In the United States, triple negative breast cancer (TNBC) represents 15 to 20% of all BC. When compared with other subtypes of BC, TNBC tends to present in younger women, and has a higher mortality rate of 40% in advanced stages within the first 5 years after diagnosis. TNBC has historically had limited treatment options when compared to other types of BC. The mainstay of treatment for TNBC remains cytotoxic chemotherapy despite the emergence of new biologic and targeted agents. Defining the specific tumor molecular profile including PDL-1 and androgen receptor testing is expanding treatment options in the clinical setting. Identifying more targetable, novel biomarkers that may better define therapeutic targets or prognostic markers is currently underway. TNBC nomenclature is expected to be updated in favor of other nomenclature which would help direct therapy, and further redefine TNBC’s heterogeneity. Given the continuous advances in the field of TNBC, this review assesses the latest developments in basic characterization, subtyping, and treatment of TNBC, including novel drug developments with antibody-drug conjugates, immune checkpoint inhibitors, PARP inhibitors and androgen receptor targeted agents. Future trials are necessary in the face of these innovations to further support the use of new therapies in TNBC and the detection of the appropriate biomarkers.

show abstract

Section: Chemotherapy For Triple Negative Breast Cancermentioning

confidence: 99%

Section: Chemotherapy For Triple Negative Breast Cancermentioning

confidence: 99%

Section: Chemotherapy For Triple Negative Breast Cancermentioning

confidence: 99%

See 1 more Smart Citation

Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021

Zerdan

Ghorayeb

Saliba

et al. 2022

Cancers

100

View full text Add to dashboard Cite

show abstract

“…Nevertheless, pCR tended to be worse in the cisplatin- containing group than in the doxorubicin–cyclophosphamide group for BRCA carriers with early HER2-negative BC ( Tung et al, 2020b ). The BrightTNess trial demonstrated that the addition of carboplatin increased pCR ( Loibl et al, 2018a ) and improved event-free survival ( Loibl, 2021 ) compared with paclitaxel alone in unselected TNBC patients. Therefore, for germline BRCA mutation carriers with BC treated with neoadjuvant therapy, the routine addition of platinum to anthracycline and taxane-based chemotherapy is not supported.…”

Section: Treatment Of Breast Cancer With Brca1 Mut...mentioning

confidence: 99%

BRCA1 and Breast Cancer: Molecular Mechanisms and Therapeutic Strategies

Tan

Song

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Breast cancer susceptibility gene 1 (BRCA1) is a tumor suppressor gene, which is mainly involved in the repair of DNA damage, cell cycle regulation, maintenance of genome stability, and other important physiological processes. Mutations or defects in the BRCA1 gene significantly increase the risk of breast, ovarian, prostate, and other cancers in carriers. In this review, we summarized the molecular functions and regulation of BRCA1 and discussed recent insights into the detection and treatment of BRCA1 mutated breast cancer.

show abstract

“…Pharmaceuticals 2021, 14, 1270 2 of 24 TNBC patients do not benefit from antihormonal or anti-HER2 therapy and receive conventional chemotherapy including doxorubicin (adriamycin), cyclophosphamide, and paclitaxel [15,16] (Figure 1). Platinum agents such as carboplatin are of increasing interest in gBRCA MUT , and more recently in BRCA-wild type (BRCA WT ) patients [15,17]. Paradoxically, TNBC patients tend to have a higher pathologic complete response (pCR) rate in the neoadjuvant setting (35-50%) versus other breast cancer subtypes, but still have poorer outcomes [18,19].…”

Section: Introductionmentioning

confidence: 99%

Expanding the Use of PARP Inhibitors as Monotherapy and in Combination in Triple-Negative Breast Cancer

2021

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, and is known to be associated with a poor prognosis and limited therapeutic options. Poly (ADP-ribose) polymerase inhibitors (PARPi) are targeted therapeutics that have demonstrated efficacy as monotherapy in metastatic BRCA-mutant (BRCAMUT) TNBC patients. Improved efficacy of PARPi has been demonstrated in BRCAMUT breast cancer patients who have either received fewer lines of chemotherapy or in chemotherapy-naïve patients in the metastatic, adjuvant, and neoadjuvant settings. Moreover, recent trials in smaller cohorts have identified anti-tumor activity of PARPi in TNBC patients, regardless of BRCA-mutation status. While there have been concerns regarding the efficacy and toxicity of the use of PARPi in combination with chemotherapy, these challenges can be mitigated with careful attention to PARPi dosing strategies. To better identify a patient subpopulation that will best respond to PARPi, several genomic biomarkers of homologous recombination deficiency have been tested. However, gene expression signatures associated with PARPi response can integrate different pathways in addition to homologous recombination deficiency and can be implemented in the clinic more readily. Taken together, PARPi have great potential for use in TNBC patients beyond BRCAMUT status, both as a single-agent and in combination.

show abstract

119O Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after ≥4 years of follow-up: BrighTNess, a randomized phase III trial

Abstract: Background: In BrighTNess, adding Cb with or without V to neoadjuvant chemotherapy significantly improved pathological complete response (pCR) with an acceptable safety profile in operable TNBC. We report EFS, OS, and second malignancies !4 years postsurgery.

Cited by 31 publications

References 0 publications

Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021

Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021

BRCA1 and Breast Cancer: Molecular Mechanisms and Therapeutic Strategies

Expanding the Use of PARP Inhibitors as Monotherapy and in Combination in Triple-Negative Breast Cancer

Contact Info

Product

Resources

About